Is this your brand? Claim it — free, and takes a minute with your business email.

Check your own brand

See your company’s Brand Profile.

Overview

Tagline Brand's website · 2026-10-04

EchoNext turns the world's most common cardiac test (12-lead ECG) into an AI-driven biomarker without requiring new hardware or retraining staff, providing actionable insights for high-risk patients. It is supported by extensive peer-reviewed, prospectively validated research.

Description Brand's website · 2026-10-04

Pathway Labs offers EchoNext, an AI-powered platform that transforms standard 12-lead ECGs into a next-generation biomarker for early detection of structural heart disease. It aims to increase new clinically significant diagnoses and integrate seamlessly into existing healthcare workflows.

Offerings

Core capabilities Brand's website · 2026-10-04

  • EchoNext
  • an AI-powered platform that analyzes standard 12-lead ECGs to detect structural heart disease.

Pricing Brand's website · 2026-10-04

Not explicitly mentioned in the provided data.

Audience

Target industry Brand's website · 2026-10-04

Health systems, hospitals, and cardiology teams seeking early and efficient detection of structural heart disease.

Is this your business?

The information above is publicly sourced — assembled by Optimly from Pathway Labs's website and public pages.

Claim this profile to add your own owner-approved information in BrandVault and speak for Pathway Labs across the Optimly Index.

Claim Pathway Labs — free →

Page last updated 2026-10-17.